We describe here a case of sustained complete response to MEK inhibition in an adolescent patient with a recurrent metastatic MPNST with multiple alterations in the MAPK pathway, guided by a precision oncology approach. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.